Skip to main content

Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b.

Publication ,  Journal Article
Patel, SJ; Liu, N; Piaker, S; Gulko, A; Andrade, ML; Heyward, FD; Sermersheim, T; Edinger, N; Srinivasan, H; Emont, MP; Westcott, GP; Yan, S ...
Published in: Sci Transl Med
March 23, 2022

Inflammation has profound but poorly understood effects on metabolism, especially in the context of obesity and nonalcoholic fatty liver disease (NAFLD). Here, we report that hepatic interferon regulatory factor 3 (IRF3) is a direct transcriptional regulator of glucose homeostasis through induction of Ppp2r1b, a component of serine/threonine phosphatase PP2A, and subsequent suppression of glucose production. Global ablation of IRF3 in mice on a high-fat diet protected against both steatosis and dysglycemia, whereas hepatocyte-specific loss of IRF3 affects only dysglycemia. Integration of the IRF3-dependent transcriptome and cistrome in mouse hepatocytes identifies Ppp2r1b as a direct IRF3 target responsible for mediating its metabolic actions on glucose homeostasis. IRF3-mediated induction of Ppp2r1b amplified PP2A activity, with subsequent dephosphorylation of AMPKα and AKT. Furthermore, suppression of hepatic Irf3 expression with antisense oligonucleotides reversed obesity-induced insulin resistance and restored glucose homeostasis in obese mice. Obese humans with NAFLD displayed enhanced activation of liver IRF3, with reversion after bariatric surgery. Hepatic PPP2R1B expression correlated with HgbA1C and was elevated in obese humans with impaired fasting glucose. We therefore identify the hepatic IRF3-PPP2R1B axis as a causal link between obesity-induced inflammation and dysglycemia and suggest an approach for limiting the metabolic dysfunction accompanying obesity-associated NAFLD.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sci Transl Med

DOI

EISSN

1946-6242

Publication Date

March 23, 2022

Volume

14

Issue

637

Start / End Page

eabh3831

Location

United States

Related Subject Headings

  • Obesity
  • Non-alcoholic Fatty Liver Disease
  • Mice
  • Interferon Regulatory Factor-3
  • Insulin Resistance
  • Animals
  • 4003 Biomedical engineering
  • 3206 Medical biotechnology
  • 11 Medical and Health Sciences
  • 06 Biological Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, S. J., Liu, N., Piaker, S., Gulko, A., Andrade, M. L., Heyward, F. D., … Rosen, E. D. (2022). Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. Sci Transl Med, 14(637), eabh3831. https://doi.org/10.1126/scitranslmed.abh3831
Patel, Suraj J., Nan Liu, Sam Piaker, Anton Gulko, Maynara L. Andrade, Frankie D. Heyward, Tyler Sermersheim, et al. “Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b.Sci Transl Med 14, no. 637 (March 23, 2022): eabh3831. https://doi.org/10.1126/scitranslmed.abh3831.
Patel SJ, Liu N, Piaker S, Gulko A, Andrade ML, Heyward FD, et al. Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. Sci Transl Med. 2022 Mar 23;14(637):eabh3831.
Patel, Suraj J., et al. “Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b.Sci Transl Med, vol. 14, no. 637, Mar. 2022, p. eabh3831. Pubmed, doi:10.1126/scitranslmed.abh3831.
Patel SJ, Liu N, Piaker S, Gulko A, Andrade ML, Heyward FD, Sermersheim T, Edinger N, Srinivasan H, Emont MP, Westcott GP, Luther J, Chung RT, Yan S, Kumari M, Thomas R, Deleye Y, Tchernof A, White PJ, Baselli GA, Meroni M, De Jesus DF, Ahmad R, Kulkarni RN, Valenti L, Tsai L, Rosen ED. Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. Sci Transl Med. 2022 Mar 23;14(637):eabh3831.

Published In

Sci Transl Med

DOI

EISSN

1946-6242

Publication Date

March 23, 2022

Volume

14

Issue

637

Start / End Page

eabh3831

Location

United States

Related Subject Headings

  • Obesity
  • Non-alcoholic Fatty Liver Disease
  • Mice
  • Interferon Regulatory Factor-3
  • Insulin Resistance
  • Animals
  • 4003 Biomedical engineering
  • 3206 Medical biotechnology
  • 11 Medical and Health Sciences
  • 06 Biological Sciences